Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Ulcerative Colitis: Update Bulletin #3 [June 2018]

Product Code:
596200963
Publication Date:
June 2018
Format:
PDF
Price:
£910

This edition presents key opinion leader (KOL) views on recent developments in the ulcerative colitis (UC) market. Topics covered include; Arena Pharmaceuticals announcing positive topline Phase II results from the OASIS trial for etrasimod, a selective sphingosine 1-phosphate (S1P) receptor modulator, in patients with UC; Atlantic Healthcare announcing that it had completed enrollment in its Phase III study of alicaforsen, an antisense oligonucleotide, in patients with IBD pouchitis; as well as Abivax announcing the completion of enrollment of its Phase IIa trial for ABX 464 in patients with moderate-to-severe UC.

Business Questions:

• What do KOLs think of the Phase II OASIS trial results for etrasimod?
• What are the experts’ views on etrasimod’s specificity for S1P receptor subtypes 1, 4 and 5?
• If approved, where would etrasimod be positioned in the UC treatment paradigm?
• What do KOLs think of alicaforsen enema as a therapy for pouchitis?
• Do KOLs believe alicaforsen enema could be used as a therapy for UC?
• How clinically attractive would a tablet formulation of alicaforsen be?
• What are KOLs’ views on Abivax’s ABX 464 as a potential treatment for UC?
• If approved, how is ABX 464 expected to be used in the UC treatment algorithm?




customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved